News
Media
Conferences
Events
Publication
CME/CE
Resources
Editorial Advisory Board
Partners
Subscribe

Opinion|Videos|July 1, 2024

Post-Relapse Treatment of a 50-Year-Old Male Patient with Vitiligo

Author(s)Anthony Nuara, MD, PhD

Continuing the discussion of a 50-year-old male patient with vitiligo, Anthony Nuara, MD, PhD, addresses the intricacies of treating patients who have relapsed or experienced a loss of efficacy following their initial treatment and highlights how to select 2nd line treatments with greater efficacy.

Episodes in this series

Anthony Nuara, MD, PhD, an expert on vitiligo

EP. 1 Vitiligo Management Strategies: A Case-Based Discussion on Treatment Challenges and Solutions

Anthony Nuara, MD, PhD, an expert on vitiligo

EP. 2 Community Physician Voices: Exploring Management Options for a 50-Year-Old Patient with Vitiligo

Anthony Nuara, MD, PhD, an expert on vitiligo

EP. 3 Post-Relapse Treatment of a 50-Year-Old Male Patient with Vitiligo

EP. 4 Vitiligo Care Personalized for Each Patient: Part 3

EP. 4 Vitiligo Care Personalized for Each Patient: Part 3

EP. 5 Vitiligo Care Personalized for Each Patient: Part 4

EP. 5 Vitiligo Care Personalized for Each Patient: Part 4

EP. 6 Discovering Dermatology Times: August 2024 Personalized Vitiligo Care Supplement

EP. 6 Discovering Dermatology Times: August 2024 Personalized Vitiligo Care Supplement

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Related Content

Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing

ByMaddi Hebebrand, MC, Associate Editor

December 10th 2025

Impaired HRQoL and High Psychological Comorbidity Observed in Japanese Vitiligo Patients

ByMarie Bosslett, Assistant Editor

December 10th 2025

AI at the Bedside: How Automated Solutions are Transforming Vitiligo Management

ByMarie Bosslett, Assistant Editor

December 9th 2025

Clear Communication Helps Reduce Patient Concerns About Boxed Warnings

ByMichael Lewitt, MD ,Maddi Hebebrand, MC, Associate Editor

November 25th 2025

Lewitt Highlights Early Treatment Benefits of Topical JAK Inhibitors

ByMichael Lewitt, MD ,Maddi Hebebrand, MC, Associate Editor

November 20th 2025

Latest CME

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Trending on Dermatology Times

JAK Inhibitors Show Comparable Safety to TNF Antagonists

First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC

"PDE4 Inhibitor-Responsive Dermatoses": A Modern Framework for Managing Inflammatory Skin Conditions

Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2

© 2025 MJH Life Sciences^®

All rights reserved.